pimecrolimus + recombinant human epidermal growth factor

**Pimecrolimus + recombinant human epidermal growth factor** is an unmarketed topical combination investigated experimentally for potential dermatological applications, particularly in inflammatory skin conditions like atopic dermatitis. Pimecrolimus, a topical calcineurin inhibitor (**small molecule**), binds FKBP-12 to inhibit calcineurin, blocking T-cell activation and cytokine production (IL-2, IFN-γ, IL-4, IL-10), while also suppressing mast cell mediator release to reduce inflammation and itching. Recombinant human epidermal growth factor (**recombinant protein**) promotes epidermal cell proliferation, migration, and wound healing by activating EGFR signaling pathways. No clinical approval or established developer exists for this specific combination; preclinical data suggest potential interference when pimecrolimus is coadministered with cell therapies involving growth factor pathways, though direct combination studies are absent.